6th Annual 3D Cell Culture Conference

8-9 February 2022

London, UK
http://www.3D-cellculture.com/PJwl

Sponsored: CelVivo, Promega and Systemic Bio

Conference Co-chairs:

Phillip Hewitt, Global Head of Early Investigative Toxicology, Merck

Rhiannon David, Director, Microphysiological Systems, AstraZeneca 

Exploring the implementation of complex in-vitro models for drug development

Join us in February 2023, as SAE Media Group’s 6th annual 3D Cell Culture Conference brings together industry experts from big pharma, regulatory bodies, and cutting-edge researchers to discuss the challenges and drivers of these medical technologies, through case studies of the latest innovations in 3D Cell Culture models, real world examples of clinical applications, and insights into regulatory validation and high throughput screening to give a comprehensive look into this fast growing industry.

3D Cell Culture has gained increasing momentum in the pharmaceutical industry over recent years, with the global 3D Cell Culture market predicted to reach a value of $3.48 Billion by 2028. The pharmaceutical industry globally is realising the growing potential of in vitro tissue models for drug discovery, pathology modelling and validation, safety and toxicity. 3D Cell Culture technology promises to offer increased translatability in models and reduce the costly rates of drug attrition in the discovery process — heralding the next major advance in the discovery of pharmaceuticals.

Event Hashtag: #3DCellCulture2023

Key Conference Highlights:

• Discuss the uses of advanced cell technologies for human tissue bioengineering
• Uncover the major benefits of 3D modelling in enhancing clinical translation and predictability
• Utilise 3D cell culture for personalised drug screening and high-throughput screening over traditional 2D methods
• Learn how to implement 3D Cell Culture techniques for antibody and cell and gene therapy discovery process
• Delve into advanced case studies looking into organ models: from the blood-brain barrier to liver spheroids

Who Should Attend?

Biotech / Pharma Companies – Investigative toxicologist, Research Scientist, Clinical Pharmacologist, Cell Technologists, Cell and Molecular Scientist, Head of Translational Research,  In-Vitro Toxicologists,  Director of Drug Discovery, Head of DMPK, Chief Scientific Officer,  R&D Scientist, Head of R&D.

Academia – Cell Technology, Stem Cell Sciences, Biochemistry, Protein Technology and Tissue Engineering

Solution Providers – Manager, Head of, CEO, Director, Founder, Account Manager, President, CSO, Executive, Managing Director, Vice President, COO, Biomedical Engineers, Head of External Collaboration

Organisations / Regulatory – Director, Senior Science Advisor, Scientific Officer, Advisor for Toxicology